p21CIP/WAF1 saRNA inhibits proliferative vitreoretinopathy in a rabbit model
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0282063 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Qi Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Affiliated Hospital and Medical School of Nantong University, Nantong City, Jiangsu Province, China. Hauptthemen laut MEDLINE: Vitreoretinopathy, Proliferative. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: industry-university fund, Natural Sciences Foundation of China.
Abstract (Originalsprache)
Purpose
Proliferative vitreoretinopathy (PVR) is a disease process resulting from proliferation of retinal pigment epithelial (RPE) cells in the vitreous and periretinal area, leading to periretinal membrane formation and traction and eventually to postoperative failure after vitreo-retinal surgery for primary rhegmatogenous retinal detachment (RRD). The present study was designed to test the therapeutic potential of a p21 CIP/WAF1 (p21) inducing saRNA for PVR.
Methods
A chemically modified p21 saRNA (RAG1-40-53) was tested in cultured human RPE cells for p21 induction and for the inhibition of cell proliferation, migration and cell cycle progression. RAG1-40-53 was further conjugated to a cholesterol moiety and tested for pharmacokinetics and pharmacodynamics in rabbit eyes and for therapeutic effects after intravitreal administration in a rabbit PVR model established by injecting human RPE cells.
Results
RAG1-40-53 (0.3 mg, 1 mg) significantly induced p21 expression in RPE cells and inhibited cell proliferation, the progression of cell cycle at the G0/G1 phase and TGF-β1 induced migration. After a single intravitreal injection into rabbit eyes, cholesterol-conjugated RAG1-40-53 exhibited sustained concentration in the vitreal humor beyond at least 8 days and prevented the progression of established PVR. Conclusion p21 saRNA could represent a novel therapeutics for PVR by exerting a antiproliferation and antimigration effect on RPE cells.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Affiliated Hospital and Medical School of Nantong University, Nantong City, Jiangsu Province, China.
- Dalian Medical University, Lvshunkou District, Dalian City, Liaoning Province, China.
- Nantong University, Nantong City, Jiangsu Province, China.
- Ractigen Therapeutics, Nantong City, Jiangsu Province, China.
- Institute of Reproductive Medicine, Nantong University, Nantong City, Jiangsu Province, China.
ORCID-Profile: Long-Cheng Li, Aimin Sang
Förderung
- industry-university fund
- Natural Sciences Foundation of China
Zitieren
APA
Zhang, Q., Guo, Y., Kang, M., Lin, W. H., Wu, J. C., Yu, Y., Li, L. C., & Sang, A. (2023). p21CIP/WAF1 saRNA inhibits proliferative vitreoretinopathy in a rabbit model. PLOS ONE. https://doi.org/10.1371/journal.pone.0282063
Vancouver
Zhang Q, Guo Y, Kang M, Lin WH, Wu JC, Yu Y, et al. p21CIP/WAF1 saRNA inhibits proliferative vitreoretinopathy in a rabbit model. PLOS ONE. 2023. doi:10.1371/journal.pone.0282063
BibTeX
@article{Zhang2023,
author = {Zhang, Qi and Guo, Yangchen and Kang, Moorim and Lin, Wei-Hsiang and Wu, Jian-Cheng and Yu, Ying and Li, Long-Cheng and Sang, Aimin},
title = {p21CIP/WAF1 saRNA inhibits proliferative vitreoretinopathy in a rabbit model},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0282063}
}
EUVIMED